AstraZeneca will pay insitro $40M upfront, with $1.46B tied to milestones
The collaboration pairs insitro founder Daphne Koller's biology and machine-learning platform with AstraZeneca's drug-development expertise to pursue MASH and cardiomyopathy treatments.
By RuntimeWire Staff · Published · Updated
Primary source: The Wall Street Journal
Why it matters
Most of the deal's headline value depends on later development and sales milestones. The agreement will test whether insitro can turn machine-learning-led target discovery into programs AstraZeneca advances.
Insitro has signed a drug-discovery and licensing deal with AstraZeneca worth up to $1.5 billion. Under the agreement, insitro will receive $40 million upfront and may receive up to $1.46 billion more in development and commercial milestones.…